Telix Pharmaceuticals Limited
TLX
$17.60
$0.301.73%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 48.80% | 52.28% | 55.92% | 66.25% | 105.19% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 48.80% | 52.28% | 55.92% | 66.25% | 105.19% |
| Cost of Revenue | 43.82% | 47.18% | 62.87% | 49.16% | 103.14% |
| Gross Profit | 52.09% | 55.64% | 51.32% | 76.72% | 106.56% |
| SG&A Expenses | 60.18% | 63.92% | 75.72% | 65.10% | 83.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 172.44% | 174.14% | 85.86% | -87.79% | -178.88% |
| Total Operating Expenses | 47.14% | 50.58% | 103.33% | 31.89% | 76.20% |
| Operating Income | 69.56% | 73.52% | -51.62% | 590.56% | 294.85% |
| Income Before Tax | 38.89% | 42.14% | 326.34% | 395.52% | 154.61% |
| Income Tax Expenses | 126.76% | 127.38% | -235.80% | 4,011.57% | -177.93% |
| Earnings from Continuing Operations | 3.75% | 6.17% | 297.71% | 303.65% | 158.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.75% | 6.17% | 297.71% | 303.65% | 158.32% |
| EBIT | 69.56% | 73.52% | -51.62% | 590.56% | 294.85% |
| EBITDA | 62.78% | 66.58% | -47.97% | 746.58% | 357.96% |
| EPS Basic | -0.51% | 2.01% | 290.16% | 299.45% | 156.90% |
| Normalized Basic EPS | 137.36% | 141.30% | -60.10% | 389.29% | 181.98% |
| EPS Diluted | -2.59% | -0.52% | 281.97% | 294.54% | 155.46% |
| Normalized Diluted EPS | 130.34% | 137.08% | -61.76% | 383.04% | 180.18% |
| Average Basic Shares Outstanding | 4.33% | 4.33% | 4.22% | 2.21% | 2.18% |
| Average Diluted Shares Outstanding | 6.54% | 6.54% | 8.80% | 4.66% | 5.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
